Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study Comparing Anastrozole, Letrozole and Exemestane, Upfront (for 5 Years) or Sequentially (for 3 Years After 2 Years of Tamoxifen), as Adjuvant Treatment of Postmenopausal Patients With Endocrine-responsive Breast Cancer

NCT00541086 is registered in ClinicalTrials.gov with Gruppo Italiano Mammella (GIM) as lead sponsor.

NCT NCT00541086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00541086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study Comparing Anastrozole, Letrozole and Exemestane, Upfront (for 5 Years) or Sequentially (for 3 Years After 2 Years of Tamoxifen), as Adjuvant Treatment of Postmenopausal Patients With Endocrine-responsive Breast Cancer
Lead sponsor
Gruppo Italiano Mammella (GIM)
Phase
Phase 3
Overall status
Unknown status
Start date
March 31, 2007
Completion date
July 31, 2020
Enrollment
3,697 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer